CN104755473B - 2，3‑苯并二氮杂* - Google Patents

2，3‑苯并二氮杂* Download PDF

Info

Publication number
CN104755473B
CN104755473B CN201380053739.2A CN201380053739A CN104755473B CN 104755473 B CN104755473 B CN 104755473B CN 201380053739 A CN201380053739 A CN 201380053739A CN 104755473 B CN104755473 B CN 104755473B
Authority
CN
China
Prior art keywords
alkyl
base
amino
dimethyl
methanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380053739.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755473A (zh
Inventor
S·西格尔
S·巴耶勒
A·克利夫
B·亨德勒
A·E·费尔南德斯-蒙塔尔万
U·门宁
S·克劳泽
P·勒热纳
N·施梅斯
M·布泽曼
S·霍尔顿
J·库恩克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48979774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104755473(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN104755473A publication Critical patent/CN104755473A/zh
Application granted granted Critical
Publication of CN104755473B publication Critical patent/CN104755473B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380053739.2A 2012-08-16 2013-08-13 2，3‑苯并二氮杂* Expired - Fee Related CN104755473B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102012214602.4 2012-08-16
DE102012214602 2012-08-16
DE102013202104.6 2013-02-08
DE102013202104 2013-02-08
PCT/EP2013/066931 WO2014026997A1 (de) 2012-08-16 2013-08-13 2,3-benzodiazepine

Publications (2)

Publication Number Publication Date
CN104755473A CN104755473A (zh) 2015-07-01
CN104755473B true CN104755473B (zh) 2017-03-08

Family

ID=48979774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380053739.2A Expired - Fee Related CN104755473B (zh) 2012-08-16 2013-08-13 2，3‑苯并二氮杂*

Country Status (22)

Country Link
US (1) US9890147B2 (enExample)
EP (1) EP2885286B1 (enExample)
JP (1) JP6333251B2 (enExample)
KR (1) KR20150041787A (enExample)
CN (1) CN104755473B (enExample)
AR (1) AR092129A1 (enExample)
AU (1) AU2013304146A1 (enExample)
CA (1) CA2881996A1 (enExample)
CL (1) CL2015000337A1 (enExample)
CR (1) CR20150066A (enExample)
DO (1) DOP2015000022A (enExample)
EA (1) EA201590356A1 (enExample)
EC (1) ECSP15005376A (enExample)
ES (1) ES2628005T3 (enExample)
IL (1) IL236898A0 (enExample)
MX (1) MX2015001880A (enExample)
PE (1) PE20150729A1 (enExample)
PH (1) PH12015500323A1 (enExample)
TN (1) TN2015000051A1 (enExample)
TW (1) TW201408651A (enExample)
UY (1) UY34977A (enExample)
WO (1) WO2014026997A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US20160129011A1 (en) * 2013-02-19 2016-05-12 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015121226A1 (de) * 2014-02-13 2015-08-20 Bayer Pharma Aktiengesellschaft 6-substituierte 2,3-benzodiazepine
SI3674302T1 (sl) 2014-04-23 2023-07-31 Incyte Holdings Corporation 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
WO2016062688A1 (de) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-phenyl-4,5-dihydro-3h-2,3-benzodiazepine derivatives
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2017005711A1 (de) * 2015-07-09 2017-01-12 Bayer Pharma Aktiengesellschaft Phosphor- und schwefel-substituierte benzodiazepin-derivate
WO2017063959A1 (de) * 2015-10-15 2017-04-20 Bayer Pharma Aktiengesellschaft N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US10167293B2 (en) * 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
CR20190027A (es) 2016-06-20 2019-05-16 Incyte Corp Formas sólidas cristalinas de un inhibidor de bet
WO2017191331A2 (en) 2016-08-15 2017-11-09 Givaudan Sa Organic compounds
CN109406685B (zh) * 2018-12-27 2021-05-25 湖南泰新医药科技有限公司 一种分离卡非佐米和其异构体的高效液相色谱方法
US20220079952A1 (en) * 2019-05-24 2022-03-17 Emory University Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN114920727B (zh) * 2022-05-26 2023-07-25 重庆华邦制药有限公司 一种卢帕他定的制备方法
WO2023229535A1 (en) 2022-05-27 2023-11-30 Engine Biosciences Pte. Ltd. Bet polypeptide therapeutic agents for generating synthetic lethality in tumors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807851A (en) * 1996-04-04 1998-09-15 Egis Gyogyszergyar Rt. 2,3-Benzodiazepine Derivatives as non-competitive AMPA
US6200970B1 (en) * 1996-02-01 2001-03-13 Schering Aktiengesellschaft 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors
WO2002050044A1 (en) * 2000-12-21 2002-06-27 EGIS Gyógyszergyár Rt. Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
CN1747938A (zh) * 2003-02-04 2006-03-15 伊瓦克斯药品研究院有限公司 新的取代的2,3－苯并二氮杂䓬衍生物
WO2008124075A1 (en) * 2007-04-02 2008-10-16 Teva Pharmaceutical Industries Ltd. Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3483186A (en) * 1966-11-22 1969-12-09 Mcneilab Inc 2-benzazepine derivatives
HU208429B (en) 1991-05-03 1993-10-28 Gyogyszerkutato Intezet Process for producing 1-/3-chloro-phenyl/-4-methyl-7,8-dimethoxy-5h-2,3-benzodiazepine of high purity
KR100255493B1 (ko) 1991-10-11 2000-08-01 가마쿠라 아키오 골조송증 치료제
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
WO1994026718A1 (fr) 1993-05-13 1994-11-24 Yoshitomi Pharmaceutical Industries, Ltd. Compose de 3-aminoazepine et son utilisation pharmaceutique
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
CA2258053A1 (en) 1996-06-12 1997-12-18 Yoshihisa Yamamoto Cytokine production inhibitors, triazepine compounds, and intermediates thereof
DE69717160T2 (de) 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
EP1296960A2 (en) 2000-06-16 2003-04-02 Annovis, Inc. 5h-2,3-benzodiazepine antagonists of excitatory amino acid receptors
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
GB0503962D0 (en) 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
EP1979308A1 (en) * 2005-12-30 2008-10-15 EGIS Gyógyszergyár Nyrt Optical isomers of dihydro-2,3-benzodiazepines and their stereoselective synthesis
DE102006042439A1 (de) 2006-09-09 2008-03-27 Saltigo Gmbh Verfahren zur katalytischen Herstellung von aromatischen oder heteroaromatischen Nitrilen
JP2008308491A (ja) * 2007-05-11 2008-12-25 Gunma Univ がん治療用の遊走阻害剤
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
WO2011037128A1 (ja) * 2009-09-28 2011-03-31 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤
US9102677B2 (en) 2009-11-05 2015-08-11 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2902030B1 (en) * 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200970B1 (en) * 1996-02-01 2001-03-13 Schering Aktiengesellschaft 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors
US5807851A (en) * 1996-04-04 1998-09-15 Egis Gyogyszergyar Rt. 2,3-Benzodiazepine Derivatives as non-competitive AMPA
WO2002050044A1 (en) * 2000-12-21 2002-06-27 EGIS Gyógyszergyár Rt. Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
CN1747938A (zh) * 2003-02-04 2006-03-15 伊瓦克斯药品研究院有限公司 新的取代的2,3－苯并二氮杂䓬衍生物
WO2008124075A1 (en) * 2007-04-02 2008-10-16 Teva Pharmaceutical Industries Ltd. Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents

Also Published As

Publication number Publication date
KR20150041787A (ko) 2015-04-17
JP6333251B2 (ja) 2018-05-30
ECSP15005376A (es) 2015-12-31
IL236898A0 (en) 2015-03-31
EP2885286B1 (de) 2017-03-22
WO2014026997A1 (de) 2014-02-20
CA2881996A1 (en) 2014-02-20
TW201408651A (zh) 2014-03-01
CL2015000337A1 (es) 2015-05-04
AU2013304146A1 (en) 2015-02-26
PE20150729A1 (es) 2015-06-14
EA201590356A1 (ru) 2015-07-30
EP2885286A1 (de) 2015-06-24
HK1208443A1 (en) 2016-03-04
TN2015000051A1 (en) 2016-06-29
ES2628005T3 (es) 2017-08-01
PH12015500323A1 (en) 2015-03-30
CN104755473A (zh) 2015-07-01
CR20150066A (es) 2015-04-17
AR092129A1 (es) 2015-03-25
JP2015529192A (ja) 2015-10-05
UY34977A (es) 2014-03-31
DOP2015000022A (es) 2015-09-15
US9890147B2 (en) 2018-02-13
MX2015001880A (es) 2015-05-11
US20150203483A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
CN104755473B (zh) 2，3‑苯并二氮杂*
CN103443100B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CN105492436A (zh) 取代的苯基-2,3-苯并二氮杂环庚三烯
CN105263919A (zh) 二环2,3-苯并二氮杂*和螺环取代的2,3-苯并二氮杂*
HK1197063A1 (en) Heterocyclyl aminoimidazopyridazines
CN103687858A (zh) 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
JP2016509036A (ja) Ｍｋｎｋ１阻害剤としての置換イミダゾ［１，２−ｂ］ピリダジン
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors
EP2958922A1 (de) Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen
CN117986251A (zh) 4H-吡咯并[3,2-c]吡啶-4-酮化合物
JP2018528159A (ja) 芳香族スルホンアミド誘導体
CN104837841A (zh) 用于治疗过度增殖性疾病的取代的吲唑-吡咯并嘧啶
WO2015121268A1 (de) 1-phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen-inhibitoren
WO2015121230A1 (de) 9-substituierte 2,3-benzodiazepine
WO2015121227A1 (de) 6,9-disubstituierte 1 -phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen- inhibitoren
WO2015121226A1 (de) 6-substituierte 2,3-benzodiazepine
HK1208443B (en) 2,3-benzodiazepines
CN103649087B (zh) 取代的咪唑并吡啶及其中间体
HK40069903B (zh) 4h-吡咯并[3，2-c]吡啶-4-酮化合物
HK40074720B (zh) [1,2,4]三唑并[1,5-c]喹唑啉-5-胺
HK40035008B (zh) 杂环基氨基取代的三唑类化合物作为rho相关蛋白激酶的调节剂
HK1206009A1 (en) Amino-substituted imidazopyridazines
HK1206009B (en) Amino-substituted imidazopyridazines
HK1199732B (en) Amino-substituted imidazopyridazines
HK1199732A1 (en) Amino-substituted imidazopyridazines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208443

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1208443

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170308

Termination date: 20200813

CF01 Termination of patent right due to non-payment of annual fee